The GLP-1 trend isn't slowing down. But your spend can
Embla gives health plans a clinically validated way to cover GLP-1s with predictable costs. Behavior-led care that keeps doses low and taper rates high.
GLP-1 demand is here, and growing
Why conventional GLP-1 coverage falls short
Full-dose prescriptions can quickly overwhelm your medical trend.
Without coaching, members often regain weight or stop treatment early.
Most solutions don’t taper, driving long-term costs and dependency.
A proven, cost-controlled GLP-1 program
We combine low-dose GLP-1s with ACT-based coaching and tapering, delivering up to 85% better outcomes than meds alone.
Boosted engagement
1:1 coaching, digital tracking, and flexible care plan, without extra work for your team.
Improved outcomes
Members see improvements in weight, energy, mental health, and metabolic risk.
Lower claims
Our low-dose approach reduces both pharmacy and chronic condition costs.
A strategic edge
Stand out with a high-demand solution that meets member needs and controls trend, all with predictable, under-$500 PEPM pricing.
Real world-results.
Real-world savings.
We keep employees on the lowest effective dose — saving thousands per person.
Embla members lose significantly more weight than users of GLP-1s without coaching 40–85% more.
Backed by data: lower A1c, blood pressure, cholesterol, and long-term obesity-related costs.
Programs that fit every population
Metabolic care built around behavior change, medication when needed, and long-term support.
Behavior-first metabolic care
GLP-1 + behavior change
Weight maintenance support
Easy to offer, built to scale
Getting started with Embla is fast and seamless. We handle everything so you don’t have to.
01. Connect with us
We’ll schedule your launch data and get aligned on goals and participants.
02. We take care of setup
Our team handles onboarding, communications, and custom roll out materials. No integration or extra work on your end.
03. Start changing lives
Our program is up and running in within 1-2 weeks. We’ll keep you updated on engagement, results, and health improvements.
Backed by real-world data from over 2,700 members
Our TRIM study, presented at ECO2025, proves our approach works:
16.7% avg. weight loss in 12 months
Only 45% of the full semaglutide dose used
100% of members with a week-64 weight lost >5%
85.3% lost >10%
No difference in outcomes across BMI groups
Easy to launch. Easy to love.
Embla is fully managed and plug-and-play. No complicated onboarding. No surprises.
Ready to offer a smarter GLP-1 benefit?
Let’s talk about how Embla can help you reduce GLP-1 spend and raise the standard of care.